VIRALEZE™ COVID-19 nasal spray to be ready for market Q1CY219 Dec 2020 23:55
IMO, I would rather take the nasal spray than the vaccine injection.
Melbourne, Australia; 10 December 2020:
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced significant commercial and regulatory progress has been made for VIRALEZE™ nasal spray with the EU regulatory dossier more than 90% complete and VIRALEZE™ now on track to be registered, and ready for market in Q1 CY2021. This timing is earlier than previously announced.
EU regulatory dossier >90% complete and VIRALEZE™ now on track to be registered, and ready for market in Q1 CY2021, earlier than previously announced. Initial launch batches of VIRALEZE™ scheduled for manufacture in January 2021; Starpharma is also building inventory of components and raw material to support
rapid roll-out. Launch and marketing preparations well advanced, including discussions with pharmacy chains,
B2B customers, qualitative and quantitative consumer market research; partnering discussions are continuing in parallel. VIRALEZE™ clinical study in healthy volunteers to commence in January 2021, for completion in Q1 CY2021 SPL7013 has been shown to be virucidal, inactivating more than 99.99% of SARSCoV-2 and Scripps Research Institute mechanistic studies have confirmed potent inhibition of viral ‘spike protein’ binding (>90%). The broad spectrum antiviral activity of VIRALEZE™ is a compelling differentiating feature and Starpharma is continuing to build additional efficacy data in other respiratory viruses to further broaden the product claims for VIRALEZE™
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201209:nASX1kr0yV